Stratpharma Advances Care For Radiation Dermatitis With StrataXRT

SAN DIEGO--(BUSINESS WIRE)--Stratpharma Inc. USA, a U.S. subsidiary of Stratpharma AG, the Swiss company that specializes in innovative film-forming full-contact topical medical products to improve medical and aesthetic outcomes in oncology post-procedure care, is pleased to announce the launch of StrataXRT®, the first and only topical film-forming wound dressing specifically designed to manage radiation dermatitis. Stratpharma’s groundbreaking StrataXRT is listed by the U.S. Food and Drug Administration (FDA).

Radiation dermatitis is an acute skin reaction affecting approximately 95% of patients who receive radiation therapy in cancers like breast, groins or perineum^1,2,3. It generally ranges from erythema to dry or even moist desquamation, and can be a source of significant pain, discomfort and psychological distress.

Specifically developed for use on radiation dermatitis, toxic and compromised skin, superficial wounds, first and second degree burns, irritated, dry and itchy skin, and red and inflamed skin, StrataXRT is an innovative, flexible wound dressing that helps to promote a moist wound healing environment for rapid healing and faster re-epithelialization, post radiation therapy. StrataXRT dries to form a protective layer, which prevents the early symptoms of radiation dermatitis, significantly reduces the skin’s acute inflammatory response, and provides relief of redness/discoloration, itching, discomfort, and pain. It is an ideal solution for large surface areas and contoured skin, including breasts, face, back and pelvic area, and joints.

StrataXRT can assist radiation oncologists and radiation oncology nurses in providing the best outcome for their patients by helping manage radiation dermatitis and improving quality of life. StrataXRT also provides an easy to use topical wound dressing for patients continuing their post-therapy care at home, and can be covered with makeup or sunscreen once dry.

“StrataXRT represents a significant advancement in the management of radiation dermatitis, while substantially reducing cost for health care providers and patients,” said James Kone Jr., Executive Vice President of Sales & Business Development at Stratpharma Inc. USA. “This is the first film-forming wound dressing of its kind available in the U.S. for oncology professionals and patients.”

Stratpharma’s StrataXRT is available in the U.S. to patients exclusively through their physicians. For more information on Stratpharma Inc. USA and Stratpharma products, please visit www.stratpharma.com.

About Stratpharma

Stratpharma Inc. USA is a U.S. subsidiary of Stratpharma AG, the Swiss company that specializes in innovative film-forming full-contact topical medical products to improve medical and aesthetic outcomes in post-procedure care in aesthetic dermatology, plastic surgery, and oncology. Headquartered in San Diego, California, Stratpharma Inc. USA is responsible for bringing product distribution and education to U.S. healthcare professionals and patients. In addition to the U.S., Stratpharma products are registered in more than 80 countries and sold in over 50 countries all over the world. For more information, visit www.stratpharma.com or call Stratpharma Inc. USA at 619.930.5788.

References
1. Porock D & Kristjanson L. European Journal of Cancer Care 1999;8:143-153
2. Kedge E. Radiography 2009;15:247-257
3. Wells M et al. Radiation skin reactions. In: Faithfull S et al. Supportive care in radiotherapy. London: Elsevier; 2003. p. 135–159